The pCas9‐survivin (a typical CRISPR/Cas9 plasmid that targets and knockouts the survivin gene) delivered by LBP was used to evaluated the in vivo gene editing and anti‐cancer efficiencies through the nude mouse orthotopic HCC model. This evidence concerns the gene BIRC5 and hepatocellular carcinoma.